Spondylolisthesis is a spinal condition in which one vertebra slips forward or backward over the vertebra below it. The most common form is degenerative spondylolisthesis, which develops gradually as the spinal discs and facet joints age and lose their structural integrity. The result is instability, lower back pain, and sometimes nerve compression that causes radiating pain, tingling, or weakness in the legs.
This regenerative approach represents an emerging regenerative approach that may help address the disc and soft tissue degeneration contributing to vertebral instability – offering an option between ongoing conservative care and surgical intervention.
Understanding Spondylolisthesis Symptoms
Spondylolisthesis symptoms vary based on the degree of slippage and whether nerve structures are affected. Common presentations include:
- Chronic lower back pain that is worse with standing or walking
- Stiffness in the lower back or reduced range of motion
- Radiating pain, numbness, or tingling down one or both legs (radiculopathy)
- Muscle tightness or spasm in the lower back or hamstrings
- In more severe cases, neurogenic claudication – leg pain that worsens with walking and improves with rest
Severity is graded using the Meyerding classification from Grade I (less than 25% slippage) to Grade IV (75–100% slippage). Most patients with symptomatic degenerative spondylolisthesis have Grade I or II slippage.
Conventional Treatment for Spondylolisthesis
Standard lumbar spondylolisthesis treatment follows a conservative-to-surgical progression:
- Physical therapy to strengthen stabilizing muscles and improve posture
- Non-steroidal anti-inflammatory drugs (NSAIDs) for pain management
- Epidural steroid injections for nerve-related pain
- Bracing in some cases
- Surgery (spinal fusion) for severe or neurologically compromising cases
For many patients, conservative management provides adequate symptom control. However, a portion of patients experience persistent pain and functional limitation despite physical therapy and injections, yet do not want – or are not good candidates for – spinal fusion surgery.
Spinal fusion, while effective for appropriate cases, involves permanently eliminating motion at the fused level and carries risks including adjacent segment degeneration over time (Ghiselli et al., J Bone Joint Surg Am., 2004).
How MSC-based treatment for spondylolisthesis Works
Regenerative therapy for spondylolisthesis targets the degenerative disc and supporting tissue changes that contribute to vertebral instability. Mesenchymal stem cells (MSCs) – typically derived from bone marrow aspirate concentrate (BMAC) or adipose tissue – are injected into the intervertebral disc or surrounding structures.
MSCs in this context are thought to work through several mechanisms:
- Disc regeneration support: MSCs may help maintain or partially restore disc cell populations (nucleus pulposus cells) and extracellular matrix components that give discs their shock-absorbing properties
- Anti-inflammatory signaling: MSCs release paracrine factors that reduce local inflammatory mediators contributing to pain and degeneration
- Structural support: By addressing disc degeneration, MSC therapy may help stabilize the vertebral segment and reduce the progressive instability characteristic of spondylolisthesis
What the Evidence Shows
A pivotal pilot study by Orozco and colleagues demonstrated the feasibility and safety of intradiscal MSC injection for lumbar disc degeneration. Patients receiving autologous bone marrow MSC injections showed significant improvements in pain, disability, and quality of life at 12 months, along with evidence of disc hydration recovery on MRI (Orozco et al., Transplantation, 2011).
Centeno and colleagues have contributed extensively to the safety and outcomes literature on MSC-based treatment for spinal conditions, including reporting favorable results in patients with disc-related and facet-related spinal pathology (Centeno et al., Curr Stem Cell Res Ther.*, 2011).
Cell-based therapeutics for intervertebral disc repair have also shown promise in clinical experience, with evidence that introducing reparative cells into degenerated discs can slow or partially reverse degenerative changes (Meisel et al., Biomol Eng., 2007).
Patient Selection Considerations
MSC injection treatment is most appropriate for patients who:
- Have Grade I or II degenerative spondylolisthesis
- Have persistent symptoms despite at least 3–6 months of conservative treatment
- Do not have severe neurological compromise requiring urgent surgical decompression
- Do not have significant spinal instability requiring fusion
- Are not current smokers (smoking impairs disc cell viability and regenerative responses)
A thorough evaluation, including current imaging (MRI or CT), clinical history, and functional assessment, is essential to determine whether regenerative treatment is appropriate.
Frequently Asked Questions
Can stem cell therapy replace surgery for spondylolisthesis?
For mild-to-moderate cases without severe neurological compromise, stem cell therapy may help manage symptoms and potentially slow progression, offering an alternative to surgical fusion. It is not a substitute for surgery in cases with severe instability or significant nerve compression.
How long does recovery take after stem cell injection for spondylolisthesis?
Patients typically reduce loading activities for 2–4 weeks after injection. Improvement in pain and function may develop over 3–6 months as the disc and surrounding structures respond to treatment.
Is the procedure painful?
The injection is performed under imaging guidance (fluoroscopy or ultrasound) with appropriate anesthesia. Most patients experience manageable discomfort during the procedure and mild soreness afterward.
How does this differ from a cortisone epidural injection?
Cortisone injections reduce inflammation and provide temporary pain relief but do not address disc degeneration or structural instability. Stem cell therapy aims to support tissue repair at the source of the problem.
Key Takeaways
- This regenerative option uses MSCs to address disc degeneration and reduce the instability that drives symptoms
- Common spondylolisthesis symptoms include lower back pain, stiffness, and leg pain from nerve involvement
- MSC injections target the disc and surrounding structures through anti-inflammatory, regenerative signaling
- Clinical studies show promising outcomes for disc degeneration with intradiscal MSC treatment
- Patient selection matters – moderate severity without severe neurological compromise is the ideal candidate profile
- This approach may serve as an option between conservative care and spinal fusion for appropriate patients
To find out whether stem cell therapy at Ways2Well may be right for your spine condition, schedule a stem cell therapy consultation or schedule a consultation with our medical team.
References
- Orozco L, Soler R, Morera C, Alberca M, Sánchez A, García-Sancho J. “Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study.” Transplantation. 2011;92(7):822–828. DOI: https://doi.org/10.1097/TP.0b013e3182298a15
- Centeno CJ, Schultz JR, Cheever M, et al. “Safety and complications reporting update on the re-injection of culture-expanded mesenchymal stem cells using autologous platelet lysate technique.” Curr Stem Cell Res Ther. 2011;6(4):368–378. DOI: https://doi.org/10.2174/157488811797904033
- Ghiselli G, Wang JC, Bhatia NN, Hsu WK, Dawson EG. “Adjacent segment degeneration in the lumbar spine.” J Bone Joint Surg Am. 2004;86(7):1497–1503. DOI: https://doi.org/10.2106/00004623-200407000-00011
- Meisel HJ, Siodla V, Ganey T, Minkus Y, Hutton WC, Alasevic OJ. “Clinical experience in cell-based therapeutics: disc chondrocyte transplantation.” Biomol Eng. 2007;24(1):5–21. DOI: https://doi.org/10.1016/j.bioeng.2006.07.002
Author: Ways2Well Editorial Team
Reviewed by: Scientific Advisory Board member